liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Surrogate Biomarkers of Disease Progression in Human Pegivirus Seropositive Human Immunodeficiency Virus-Infected Individuals
Cent Univ Tamil Nadu, India.
Xiamen Univ Malaysia, Malaysia.
Govt Theni Med Coll & Hosp, India.
Cent Univ Tamil Nadu, India.
Show others and affiliations
2023 (English)In: Viral immunology, ISSN 0882-8245, E-ISSN 1557-8976, Vol. 36, no 1, p. 55-62Article in journal (Refereed) Published
Abstract [en]

Scientific observations indicate that an actively prevailing systemic condition could alleviate the pathology of another disease. Human pegivirus (HPgV), a highly ubiquitous flavivirus is believed to be associated with slow human immunodeficiency virus (HIV) disease progression, and has seldom been linked to hepatic pathology. In this study, we investigated whether HPgV seropositivity had any impact on surrogate markers of HIV disease progression in a cohort of HIV-infected HPgV seropositive (n = 28) and seronegative (n = 12) individuals who were prospectively evaluated for absolute CD4+ T cell counts, plasma viral load (PVL), liver enzymes, and plasma cytokine levels. The HIV PVL was relatively lower in HPgV seropositive than in HPgV seronegative HIV-infected subjects. Clinical markers of hepatic injury were significantly low among HPgV seropositive HIV-infected participants. HPgV seropositive individuals showed significantly higher levels of interleukin-7 (IL-7), and although not significant, the levels of IL-6 were lower among HPgV seropositive subjects. Spearman correlation analysis showed that the absolute CD4+T cell count was inversely correlated with HIV PVL. Exposure to HPgV appears to have a positive prognostic impact on the levels of surrogate biomarkers of HIV disease progression.

Place, publisher, year, edition, pages
MARY ANN LIEBERT, INC , 2023. Vol. 36, no 1, p. 55-62
Keywords [en]
cytokines; HIV; HPgV; liver enzymes; plasma viral load
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-190204DOI: 10.1089/vim.2022.0144ISI: 000883085000001PubMedID: 36355180Scopus ID: 2-s2.0-85146484271OAI: oai:DiVA.org:liu-190204DiVA, id: diva2:1714435
Note

Funding Agencies|Department of Science and Technology-Science and Engineering Research Board, Government of India [CRG/2019/006096]; Swedish Research Council [AI52731]; Swedish, Physicians against AIDS Research Foundation; Swedish International Development Cooperation Agency; SIDA SARC, VINNMER; NIH Office of Research Infrastructure Programs [P51 OD011132]; Emory CFAR [P30 AI050409]

Available from: 2022-11-29 Created: 2022-11-29 Last updated: 2024-04-10

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Larsson, Marie

Search in DiVA

By author/editor
Larsson, Marie
By organisation
Division of Molecular Medicine and VirologyFaculty of Medicine and Health Sciences
In the same journal
Viral immunology
Immunology in the medical area

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 743 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf